Biotek-snakken — Marts 2024
-
Calliditas: Extended US Tarpeyo brand protection
"Our base case (SEK 270)"
"The extended exclusivity period makes our base case even more conservative. We are not making any positive revisions at this stage"
-
-
Norske Ultimovacs venter på topline resultatet fra fase II studiet INITIUM. Det er lovet at resultaterne kommer her i marts 2024.
I det norsk investor-miljø er der mange som venter med spændning på resultaterne. Dette gælder lige fra større investorer i selskabet til mange små-aktionærer. Men hvorfo det? - Det lkræver en forklaring https://www.proinvestor.com/boards/119174/
-
God morgen
-
"Trots framgångarna med Ximluci anser Xbrane Biopharma att det finns betydligt mer potential att hämta för biosimilaren. Bolaget är aktuellt med en företrädesemission på 343 Mkr och genomför samtidigt ett sparprogram, med sikte på att bli kassaflödespositivt senast Q1 2025. Ett viktigt steg på den resan blir att lansera produkten i USA."
-
BioStock Investor Pitch: Xbrane Biopharma
-
5 Biotech Stocks With 26% Upside Potential or More https://www.proinvestor.com/investornyt/1128777/5-biotech-stocks-with-26-upside-potential-or-more
-
Stroka..Gubra er forholdvis illikvid og derfor pænt volatil for at sige det mildt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind